VividWhite Glaucoma Implant (VW-51) Pivotal Study

Glaucoma Clinical Trial

Official title:

A Prospective Multicentre Pivotal Clinical Study to Demonstrate the Efficacy and Safety of the VividWhite Glaucoma Implant (VW-51) for the Treatment of Glaucoma.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06176170
• Other study ID #: DF-550
• Status: Recruiting
• Phase: N/A
• Start date: December 12, 2023
• Est. completion date: December 2025

Study information

• Verified date: May 2024
• Source: VividWhite Pty Ltd
• Contact: Andrew Batty
• Phone: +61 418 213 895
• Email: contact[@]vividwhite.com.au
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The VividWhite Glaucoma Implant (VW-51) is a novel surgical implant designed to treat glaucoma. This study is a 12-month, 65-participant non-comparative multicentre study to assess the safety and effectiveness of the VW-51 implant.

Description:

A prospective multicentre non-comparative pivotal clinical study where all participants undergo treatment with a novel surgical implant (VW-51) and receive 12 months of clinical follow-up. The study aim is to assess the effectiveness, safety and participant experience of the VW-51 implant for the treatment of glaucoma. The study population will involve 65 adult participants with medically or surgically refractory glaucoma. The VW-51 implant is a leaf-shaped microfluidic device manufactured from flexible silicone, designed to be surgically implanted in the subconjunctival space, drain aqueous humor from the eye and reduce intraocular pressure to treat glaucoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 65
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria: Glaucoma in the study eye, meeting the following requirements:

1. Glaucoma is diagnosed by the investigator based upon untreated intraocular pressure, disc appearance and visual field abnormalities, and where the disease type is one of: Primary open angle glaucoma (POAG); Chronic angle closure glaucoma (CACG) where the eye is pseudophakic and a laser iridotomy has previously been performed; Pigmentary open angle glaucoma; Exfoliation open angle glaucoma; Rubeotic glaucoma that is treated and regressed/quiescent; Steroid-induced glaucoma; or Juvenile open angle glaucoma (JOAG).

2. There has been failure of previous treatment for glaucoma (it is 'refractory'), meeting ONE of the following requirements:

i. Failure of medical treatment: inadequate IOP control on maximum tolerated medical therapy.

ii. Failure of previous glaucoma surgery (not more than one operation) with trabeculectomy, Xen/PreserFlo, non-penetrating glaucoma surgery, a previously removed suprachoroidal drainage device, trabecular bypass (using iStents or Hydrus), or cilioablation.

c. The mean diurnal IOP at Screening/Baseline is = 20 mmHg, and = 40 mmHg.

d. The conjunctiva in the target quadrant is healthy, mobile and suitable for glaucoma surgery.

Key Exclusion Criteria: in the study eye:

1. Advanced glaucomatous optic neuropathy that threatens fixation, in the opinion of the investigator.

2. The glaucoma type is any of the following: Acute Angle Closure Glaucoma (AACG); Chronic Angle Closure Glaucoma where the eye is phakic; Congenital glaucoma; or Secondary glaucoma of any type not specified in the inclusion criteria, including inflammatory glaucoma, active neovascular/rubeotic glaucoma, traumatic glaucoma, Iridocorneal Endothelial (ICE) Syndrome, and silicone oil induced glaucoma.

3. Previous glaucoma surgery with: a tube-and-plate glaucoma drainage device (GDD, e.g. Molteno, Baerveldt, Ahmed, Schocket); an in-situ suprachoroidal implant; or multiple previous operations for glaucoma.

4. Cataract surgery or any other ocular surgery is indicated at the time of study intervention or is anticipated to be required during the study duration.

5. Central corneal endothelial cell density less than specified age-related thresholds at screening.

6. Intraocular silicone oil.

7. Significant corneal, retinal, inflammatory or infective ophthalmic pathology (full details specified in the protocol).

Related Conditions & MeSH terms

• Glaucoma

Intervention

Device:
• VividWhite Glaucoma Implant (VW-51)
Subconjunctival surgical implantation of the VW-51 implant in the study eye.

Locations

Country	Name	City	State
Australia	Cataract & Eye Surgery Centre	Doncaster East	Victoria
Australia	Melbourne Eye Specialists	Fitzroy	Victoria
Australia	Sydney Eye Hospital	Sydney	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
VividWhite Pty Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete success by efficacy and safety criteria	Efficacy Criteria: Intraocular pressure (IOP) is less than or equal to 21 mmHg.; IOP is reduced by greater than or equal to 20% compared to baseline (mean diurnal).; Treatment with the same number or fewer classes of topical glaucoma medication than at baseline.; No requirement for: further glaucoma surgery indicated for efficacy (at any time during the study); or systemic/oral ocular hypotensive medication to achieve target IOP in the study eye (at any time during the study).; Safety Criteria: IOP is greater than or equal to 6 mmHg.; No adverse events of special significance in the study eye (as specified by the protocol; for example further glaucoma surgery indicated for safety).	Study completion (12 months)